Head-To-Head Analysis: Atossa Genetics (NASDAQ:ATOS) vs. Tandem Diabetes Care (NASDAQ:TNDM)

Tandem Diabetes Care (NASDAQ:TNDM) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Earnings and Valuation

This table compares Tandem Diabetes Care and Atossa Genetics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01 billion	1.65	-$204.71 million	($3.07)	-7.98
Atossa Genetics	N/A	N/A	-$25.50 million	($3.60)	-1.53

Atossa Genetics has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tandem Diabetes Care has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 9.5% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Tandem Diabetes Care and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-20.17%	-68.23%	-11.07%
Atossa Genetics	N/A	-49.42%	-44.76%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tandem Diabetes Care and Atossa Genetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1	9	8	1	2.47
Atossa Genetics	2	0	2	1	2.40

Tandem Diabetes Care currently has a consensus target price of $29.22, indicating a potential upside of 19.23%. Atossa Genetics has a consensus target price of $95.00, indicating a potential upside of 1,624.14%. Given Atossa Genetics’ higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Tandem Diabetes Care.

Summary

Atossa Genetics beats Tandem Diabetes Care on 7 of the 13 factors compared between the two stocks.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.